489 related articles for article (PubMed ID: 29325553)
1. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms.
Picatoste B; Ramírez E; Caro-Vadillo A; Iborra C; Ares-Carrasco S; Egido J; Tuñón J; Lorenzo O
PLoS One; 2013; 8(10):e78330. PubMed ID: 24302978
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
Giannocco G; Oliveira KC; Crajoinas RO; Venturini G; Salles TA; Fonseca-Alaniz MH; Maciel RM; Girardi AC
Eur J Pharmacol; 2013 Jan; 698(1-3):74-86. PubMed ID: 23051671
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
[TBL] [Abstract][Full Text] [Related]
5. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
6. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
Zhang HY; Li Y; Zhong YH; Ruan LB; Yang TR; Yin HP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
8. Sitagliptin attenuates myocardial apoptosis via activating LKB-1/AMPK/Akt pathway and suppressing the activity of GSK-3β and p38α/MAPK in a rat model of diabetic cardiomyopathy.
Al-Damry NT; Attia HA; Al-Rasheed NM; Al-Rasheed NM; Mohamad RA; Al-Amin MA; Dizmiri N; Atteya M
Biomed Pharmacother; 2018 Nov; 107():347-358. PubMed ID: 30099338
[TBL] [Abstract][Full Text] [Related]
9. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W
Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
[TBL] [Abstract][Full Text] [Related]
11. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Ramírez E; Klett-Mingo M; Ares-Carrasco S; Picatoste B; Ferrarini A; Rupérez FJ; Caro-Vadillo A; Barbas C; Egido J; Tuñón J; Lorenzo Ó
Cardiovasc Diabetol; 2013 Nov; 12():172. PubMed ID: 24261558
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
Karabulut S; Coskun ZM; Bolkent S
Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
14. Bis-Pyrano Prenyl Isoflavone Improves Glucose Homeostasis by Inhibiting Dipeptidyl Peptidase-4 in Hyperglycemic Rats.
Altenhofen D; da Luz G; Frederico MJ; Venzke D; Brich M; Vigil S; Fröde TS; Linares CE; Pizzolatti MG; Silva FR
J Cell Biochem; 2017 Jan; 118(1):92-103. PubMed ID: 27238050
[TBL] [Abstract][Full Text] [Related]
15. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
16. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway.
Wei H; Bu R; Yang Q; Jia J; Li T; Wang Q; Chen Y
J Diabetes Res; 2019; 2019():8905917. PubMed ID: 31886288
[TBL] [Abstract][Full Text] [Related]
18. [6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Lepr
Samad MB; Mohsin MNAB; Razu BA; Hossain MT; Mahzabeen S; Unnoor N; Muna IA; Akhter F; Kabir AU; Hannan JMA
BMC Complement Altern Med; 2017 Aug; 17(1):395. PubMed ID: 28793909
[TBL] [Abstract][Full Text] [Related]
19. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
